Findx
EnglishEnglish
Dansk Dansk

ABIONYX Pharma SA stock analysis ABNX.FR

ABIONYX Pharma is a French biotechnology company focused primarily on developing novel biotherapeutics for sepsis and critical care, leveraging its proprietary platform built around recombinant apoA-I (apolipoprotein A-I) and HDL-based vectors. Its lead product candidate, CER-001, comprises recombinant human apoA-I complexed with specific phospholipids, mimics nascent HDL, and is designed to ameliorate immune-inflammatory dysregulation. CER-001 is under development in multiple therapeutic indications including sepsis, lecithin cholesterol acyltransferase (LCAT) deficiency, and Norum disease, and has progressed through preclinical studies, a Phase I trial in healthy volunteers, and further Phase 2a clinical studies. The company has obtained orphan drug designation from the U.S. Food and Drug Administration for CER-001 in treating LCAT deficiency.

In addition to its therapeutic development programs, ABIONYX Pharma operates a subsidiary, IRIS Pharma, which provides contract research organization (CRO) services specializing in ophthalmology. In its most recent financial reporting, all its revenue derives from these CRO activities; its therapeutic programs currently do not generate commercial income, though CER-001 is provided free of charge under Compassionate Use Authorizations in rare disease settings. The company has also established an exclusive global strategic partnership with SEBIA to jointly develop diagnostic tests for earlier detection and monitoring of sepsis severity.

ABIONYX Pharma is headquartered in Balma, in the Occitanie region of France, and maintains operations in France and the United States. Its technology platform entails bioproduction of recombinant apoA-I and synthetic phospholipids (notably sphingomyelin), including recent achievement of fully synthetic sphingomyelin to enhance batch consistency and safety. The company secures financial support through CRO revenues, government grants (including via France's France-2030 plan), and recent capital raises and non-dilutive instruments, enabling its financial visibility through 2028.

Healthcare · Biotechnology · Biotechnology · France
Quality
Quality
Momentum
Momentum
Strength
Strength
Entry
Entry: Not yet
A short-term bounce, not yet a trend change. Price is above SMA 20, but the moving averages are still falling, so being above them reflects a bounce inside a downtrend rather than a reversal. Wait for the averages to flatten and turn up before entering.
Trend
Trend: Hold
The medium-term trend is intact. Price remains above SMA 20, and none of the profit-protection rules have triggered. Keep holding and let the trend work.
‹
›

Click to see warnings

Neg. values
‹
›
Years
Lower P/E (Bear)
Sign in to view
Fair Value
Sign in to view
Upper P/E (Bull)
Sign in to view
Analysts
Sign in to view
Price: Financials: No reliable interim period / FY2025TTM presentEstimates: , 2 analystsScored as: Standard companyEvidence: IncompleteDetails

Freshness

  • Price through:
  • Latest annual period: FY2025 (); filed
  • Latest interim period: No reliable interim period
  • TTM period: ; used by: Quality, Strength
  • Normalized EPS: , 2 analysts
  • Diluted EPS: , 2 analysts
  • Target price: , 2 analysts

Scoring profile

Effective scoring profile: Standard company

Report a suspected classification error

Score evidence

Quality: Unavailable; Not enough evidence; TTM used
Business Momentum: Score calculated; Good confidence; TTM not used
Strength: Score calculated; Limited confidence; TTM used
  • Quality score unavailable because the required anchor metric is missing. Missing: Business Development, Return on Capital.
  • Limited confidence for Strength by model design: some checks rest on only three or four full fiscal years.

Sources and adjustments

Remaining score inputs are provider supplied.

  • Debt to operating cash flow: derived by Findx
  • Net debt to EBITDA: derived by Findx
  • Normalized EPS, : historical consensus fill

Key stock metrics

Blended P/E  :
P/E (last full year) :
N/A
N/A
Blended EPS  :
EUR -0.23
Blended EPS Yield  :
N/A
Dividend Yield :
(Trailing 12 months)
0.00%
Buyback Yield :
(Trailing 12 months)
-2.34%
Market Cap:EUR 71.98 M

Valuation basis

Analyst price target
Yearly EPS growth  :
( years incl. estimate)
N/A

P/E Values

Upper P/E:
Fair Value P/E  :
Lower P/E:
Market P/E  :

EPS Estimates

:
N/A
:
N/A
:
N/A

About ABIONYX Pharma SA

Description, revenue sources, strengths and weaknesses

DESCRIPTION

ABIONYX Pharma is a French biotechnology company focused primarily on developing novel biotherapeutics for sepsis and critical care, leveraging its proprietary platform built around recombinant apoA-I (apolipoprotein A-I) and HDL-based vectors. Its lead product candidate, CER-001, comprises recombinant human apoA-I complexed with specific phospholipids, mimics nascent HDL, and is designed to ameliorate immune-inflammatory dysregulation. CER-001 is under development in multiple therapeutic indications including sepsis, lecithin cholesterol acyltransferase (LCAT) deficiency, and Norum disease, and has progressed through preclinical studies, a Phase I trial in healthy volunteers, and further Phase 2a clinical studies. The company has obtained orphan drug designation from the U.S. Food and Drug Administration for CER-001 in treating LCAT deficiency.

In addition to its therapeutic development programs, ABIONYX Pharma operates a subsidiary, IRIS Pharma, which provides contract research organization (CRO) services specializing in ophthalmology. In its most recent financial reporting, all its revenue derives from these CRO activities; its therapeutic programs currently do not generate commercial income, though CER-001 is provided free of charge under Compassionate Use Authorizations in rare disease settings. The company has also established an exclusive global strategic partnership with SEBIA to jointly develop diagnostic tests for earlier detection and monitoring of sepsis severity.

ABIONYX Pharma is headquartered in Balma, in the Occitanie region of France, and maintains operations in France and the United States. Its technology platform entails bioproduction of recombinant apoA-I and synthetic phospholipids (notably sphingomyelin), including recent achievement of fully synthetic sphingomyelin to enhance batch consistency and safety. The company secures financial support through CRO revenues, government grants (including via France's France-2030 plan), and recent capital raises and non-dilutive instruments, enabling its financial visibility through 2028.

ADDITIONAL INFO

It is very important that you understand this

Fair Value is an estimate, and you choose the basis it is built on. Do not invest based on our default without understanding how we calculate it.